Hyperfine, Inc.

NASDAQ:HYPR

Medical - Devices

Healthcare
$0.56 +15.65%

+$0.22 today

Market cap
$51.10M
Beta
1.38
P/E (TTM)
-4.5
EPS (TTM)
-$0.36
52W Low $0.66High $2.22

Volume 1.16M

Average 0.60M

HYPR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Hyperfine, Inc.NASDAQ: HYPR

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 50.7%

Gross margin was 50.7% in Q1 FY2026, up 9.4 pp from a year earlier. On a trailing-twelve-month basis it was 51.2%, up 5.0 pp year over year. Over 3 fiscal years it widened by 36.5 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
50.7%-0.2 pp QoQ
Last fiscal yearDec 2025
49.8%+4.1 pp YoY
LTMMar 2026
51.2%+5.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+9.4 pp——
1 year+4.1 pp——
3 years+36.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
49.8%
Year-over-year change
+4.1pp

Gross Margin vs competitors

How HYPR compares with its peers on the latest reported figures

  • HYPR's LTM Mar 2026 gross margin of 51.2% is the 4th highest of the 6 companies compared; the peer median is 75.5%.
  • Its year-over-year change of +5.0 pp is the highest of 6, against a peer median of -1.0 pp.
  • Over three fiscal years its change of +36.5 pp compares with a peer median of -0.2 pp.
HYPR Competitors Peer median
Gross Margin for HYPR and competitors
Company Period LTM level YoY 3-year change
CNTBConnect Biopharma Holdings LimitedFY2025100.0% +0.0 pp—
RCELAVITA Medical, Inc.LTM Mar 202681.4% -4.1 pp-0.3 pp
LUNGPulmonx CorporationLTM Mar 202675.5% +2.0 pp-0.1 pp
HYPRHyperfine, Inc.LTM Mar 202651.2% +5.0 pp+36.5 pp
FONRFONAR CorporationLTM Mar 202640.3% -1.0 pp-7.1 pp
IMAImageneBio IncFY2025-29.1% -129.1 pp+282.7 pp
VANIVivani Medical, Inc.FY2025— ——
Peer median (excluding HYPR) 75.5%-1.0 pp-0.2 pp

Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.5M6.81M11.03M12.89M13.56M
Cost of Revenue2.66M5.91M6.28M7M6.81M
Gross Profit(1.17M)907K4.76M5.89M6.75M
Gross Margin-78.0%13.3%43.1%45.7%49.8%
Research & Development25.84M28.16M22.49M22.5M17.45M
Selling, General & Admin37.86M46.63M30.38M26.62M26.39M
Operating Expenses63.7M74.78M52.87M49.12M43.84M
Depreciation & Amortization726K1.02M1.05M1.01M2.2M
EBITDA(64.13M)(72.15M)(43.18M)(39.71M)(33.37M)
EBITDA Margin-4286.4%-1058.8%-391.4%-308.1%-246.1%
Operating Income(64.87M)(73.87M)(48.12M)(43.22M)(37.09M)
Operating Margin-4336.1%-1084.2%-436.1%-335.3%-273.4%
Interest Income18K761K3.84M2.49M1.02M
Interest Expense00000
Other Income / Expenses17K710K3.88M2.5M1.51M
Income Before Tax(64.85M)(73.16M)(44.24M)(40.72M)(35.57M)
Pre-Tax Margin-4335.0%-1073.7%-401.0%-315.9%-262.3%
Income Tax Expense00000
Net Income(64.83M)(73.16M)(44.24M)(40.72M)(35.57M)
Net Margin-4333.8%-1073.7%-401.0%-315.9%-262.3%
EPS (Basic)(0.92)(1.04)(0.62)(0.56)(0.43)
EPS (Diluted)(0.92)(1.04)(0.62)(0.56)(0.43)
Weighted Avg Shares70.33M70.45M71.32M72.41M94.2M
Weighted Avg Shares (Diluted)70.33M70.45M71.32M72.41M94.2M

Hyperfine, Inc.

NASDAQ:HYPR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.